Chargement en cours...
789. Evaluation of Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection in Patients at High Risk for Recurrence
BACKGROUND: Recurrent Clostridioides difficile infection (rCDI) within 180 days of the index episode is associated with a 33% increase in mortality and, to-date, few treatment options exist to prevent recurrent infection. Bezlotoxumab (BEZ) is a novel therapeutic option for the prevention of rCDI, y...
Enregistré dans:
| Publié dans: | Open Forum Infect Dis |
|---|---|
| Auteurs principaux: | , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Oxford University Press
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7777040/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa439.979 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|